Not only does the winter season see a spike in joint issues, respiratory illnesses, urinary tract infections (UTIs), and skin ...

We spoke to actress, advocate, and philanthropist Holly Robinson Peete about her current projects and her journey with ...

CNX Therapeutics Limited (“CNX Therapeutics”), a leading European specialty pharmaceutical company, has today announced an exclusive partnership with Adalvo to commercialise a prolonged release ...

L1-blocking antibody is now approved for metastatic or locally advanced cutaneous SCC in adults who are not candidates for curative surgery or curative radiation.

Craig A Clifford, DVM, MS, DACVIM (Oncology) talks about the most common bladder tumor in dogs, misdiagnosis, and the Cadet ...

Orlando Urology Associates Albert Ong, MD; Stephen Baker, MD; Marshall Melcer, MD; Jorge Rivera Mirabal, MD ANNOUNCEMENT The ...

or ultrasounds are vital in detecting kidney stones early on and initiating prompt treatment. These tests together can reveal ...

The Food and Drug Administration (FDA) has approved Unloxcyt™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) ...

Larry Antonucci, M.D., MBA is the president & CEO of Lee Health, Southwest Florida’s major destination for health care ...

Luckily, these 12 products are recommended by thousands of Amazon reviewers and may help alleviate some discomfort, or simply ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

The virology market is projected to grow at a 5% CAGR from 2022 to 2032, reaching a valuation of US$ 3.53 billion by 2032.